Lupin Limited

BSE: 500257 NSE: LUPIN
Lupin Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24100MH1983PLC029442 Incorporated 01 March 1983 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: LUPIN · BSE: 500257 Public Limited Company pharma Fortune India 500 · #121 Nifty 500
Data last updated
Market Cap
₹87,891 Cr
LUPIN · NSE
Share Price
₹1,908.20
-0.72% today
Revenue
₹27,958 Cr
FY 2025-26 · +23.1% YoY
EBITDA
₹7,602 Cr
Margin 27.2%
Net Profit
₹5,688 Cr
FY 2025-26 · +76.4% YoY
P/E (TTM)
14.9x
P/B 4.0x
ROE
27.0%
ROCE 27.4%
Debt / Equity
0.30
Interest cover 7.0x

About Lupin Limited

Data last updated:

Lupin Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 March 1983 and has been in existence for over 43 years.

Lupin is ranked #121 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Manju D Gupta and family are #55 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24100MH1983PLC029442. Its GSTIN is 27AAACL1069K1ZF (Maharashtra). The company holds 42 GST registrations, of which 33 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500257 and NSE: LUPIN.

The company has an authorised share capital of ₹200 Cr and a paid-up capital of ₹91.45 Cr. It was formerly known as Lupin Laboratories Limited and Lajwanti Consultants and Builders Private Limited. It is led by directors including Nilesh Deshbandhu Gupta (Managing Director) and Vinita Deshbandhu Gupta (Whole-Time Director).

Its last annual general meeting (AGM) was held on 11 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹27,958 Cr, a growth of 23.1% compared to the previous year. For the same year it recorded a net profit of ₹5,687.73 Cr (net margin 20.3%) and EBITDA of ₹7,601.62 Cr (EBITDA margin 27.2%). The net worth stands at ₹22,448 Cr (up 30.5% YoY). Total assets are valued at ₹29,973 Cr (up 27.9% YoY).

The company has about 19,688 employees on its provident fund (EPFO) records. Its group structure includes 5 subsidiaries.

The company is associated with 3 brands: Humrahi, Lupin Diagnostics and Lupin. As per MCA filings, the company has open charges of ₹350 Cr and satisfied charges of ₹3,238.99 Cr on record. Court records list 720 cases involving the company, including 400 filed by the company and 322 filed against it; 169 cases are pending. The company has 46 deals on record (46 market trades); the latest was in October 2025. Its 10 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 68 MSME Form 1 returns on record between 2004 and 2024, listing 1,473 overdue payments to 395 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lupin.com.

Company details

CIN L24100MH1983PLC029442
Registration Number 029442
Incorporation Date 01 March 1983
ROC Mumbai
Listing Status Listed - Listed on NSE (LUPIN); Listed on BSE (500257)
Company Status Active
Date of Last AGM 11 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Lupin has undergone 4 name changes throughout its history. The current legal name is Lupin Limited.

Company NameStatus
Lupin LimitedCurrent
Lupin Laboratories LimitedPrevious
Lajwanti Consultants And Builders Private LimitedPrevious
Lupin Chemicals LimitedPrevious
Lupin Laboratories Private LimitedPrevious

CIN history

Lupin has one previous CIN (Corporate Identification Number): U24100MH1983PLC029442. The current CIN is L24100MH1983PLC029442, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24100MH1983PLC029442Current
U24100MH1983PLC029442Previous
Key People
Nilesh Deshbandhu Gupta Managing Director Vinita Deshbandhu Gupta Whole-Time Director Ramesh Swaminathan Whole-Time Director

Recognitions & Rankings of Lupin

Fortune India 500 2025 edition
Rank#121
Total income
₹23,167 Cr
Profit
₹3,282 Cr
Last year #120
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#72
Valuation
₹96,050 Cr
2023 #89 2022 #130 2021 #96
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Lupin Limited's registered office is in Mumbai, Maharashtra. Its website is lupin.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    lupin.com
  • Social Media
  • Registered Address
    Kalpataru Inspire 3rd Floor Off Western Express Highway Santacruz (, East), Mumbai, Maharashtra, India – 400055
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers

To see the full contact details of Lupin Limited, buy the company report.

Comprehensive company report
Lupin Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Lupin operates multiple associated brands including Humrahi, Lupin Diagnostics, and Lupin. Each brand links to its own profile.

BrandDescriptionWebsite
Humrahi
Delivers an app-based program for effective diabetes management and patient support.humrahi.co.in
Lupin Diagnostics
Operates a chain of pathology laboratory centers for diagnostic services.lupindiagnostics.com
Lupin
Pharmaceutical products including generics, biosimilars, and APIs are manufactured.lupin.com

Business activity

The main business activity of Lupin is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Lupin Limited, buy the company report.

Financials of Lupin Limited

FY 2025-26 filings available

Lupin Limited reported revenue of ₹27,958 Cr (up 23.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹27,958 Cr
+23.1% YoY
EBITDA
₹7,602 Cr
+44.0% YoY
Profit After Tax
₹5,688 Cr
+76.4% YoY
Net Worth
₹22,448 Cr
+30.5% YoY
Total Assets
₹29,973 Cr
+27.9% YoY
Total Debt
₹6,616 Cr
+21.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue27,95822,70820,01116,64216,40515,16315,375
Revenue growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
EBITDA7,6025,2783,8001,7212192,5671,603
EBITDA margin+27.2%+23.2%+19.0%+10.3%+1.3%+16.9%+10.4%
Profit before tax6,8734,0152,422716(1,372)1,676887
Net profit5,6883,2251,892410(1,561)1,177(470)
Net profit margin+20.3%+14.2%+9.5%+2.5%-9.5%+7.8%-3.1%
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
Balance sheet
Total assets29,97323,43418,01617,78917,09919,71120,071
Net worth22,44817,20414,29012,46412,15313,80312,537
Total debt6,6165,4482,9224,5424,1584,7836,305
Cash & bank5,6533,1421,2031,2931,0981,7422,454
Net working capital12,27710,1956,8667,0747,1537,9408,362
Cash flow
Cash from operations7,3343,0003,6481,8973671,8221,469
Cash from investing(3,865)(4,172)(1,712)(1,287)1,292(1,240)1,107
Cash from financing(846)1,732(2,184)(337)(1,572)(1,885)(891)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,2777,4757,1687,0486,2685,6675,7685,673
Revenue growth (YoY)+32.0%+31.9%+24.3%+24.2%+11.9%---
Other income13014111590.0079.0456.9553.7142.29
EBITDA2,4502,3541,8352,3411,7271,3211,3561,340
EBITDA margin+29.8%+31.8%+25.8%+34.3%+28.0%+23.8%+24.1%+24.4%
Depreciation453447313317299393271257
Interest11012011510891.7689.1066.8970.87
Profit before tax2,0171,9281,5222,0071,4168961,0711,055
Tax600459342522194113212195
Net profit1,4171,4691,1811,4851,221782859859
EPS (₹)30.8934.7525.6732.2826.6216.8718.6918.64
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19,51316,96814,66611,25911,77211,05611,026
Revenue growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
EBITDA7,1765,3163,4509642092,0441,148
EBITDA margin+36.8%+31.3%+23.5%+8.6%+1.8%+18.5%+10.4%
Profit before tax7,6944,8372,785527(162)1,6301,052
Net profit5,7744,0002,302411(219)1,2171,153
Net profit margin+29.6%+23.6%+15.7%+3.7%-1.9%+11.0%+10.5%
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
Balance sheet
Total assets31,87325,03721,13519,55419,43919,40917,937
Net worth30,13424,27820,60318,41218,15018,56617,473
Total debt1,1152501057499514855.83
Cash & bank12845913910164.562841,306
Net working capital8,0627,6514,8474,1874,9285,0645,959
Cash flow
Cash from operations5,5402,4452,5041,7941511,5702,219
Cash from investing(5,649)(1,766)(1,599)(1,269)(372)(2,508)(740)
Cash from financing(121)(460)(867)(498)102(53.17)(368)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1725,2354,5014,0685,7094,4864,2084,106
Revenue growth (YoY)+25.6%+16.7%+7.0%-0.9%+37.0%---
Other income10253799.8066354.1448.7955.3032.62
Total expenses3,4392,9533,5182,8932,9792,7402,8742,991
EBITDA3,7332,2829831,1762,7301,7461,3341,115
EBITDA margin+52.5%+44.3%+22.2%+30.5%+48.7%+39.8%+32.9%+28.4%
Depreciation190177179175177208153146
Interest35.5638.7736.0227.7818.9033.8519.5517.55
Profit before tax3,6102,6028681,6362,5881,5531,217984
Tax895439150278460262232176

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,2777,4757,1687,0486,2685,6675,7685,673
Revenue growth (YoY)+32.0%+31.9%+24.3%+24.2%+11.9%---
Other income13014111590.0079.0456.9553.7142.29
EBITDA2,4502,3541,8352,3411,7271,3211,3561,340
EBITDA margin+29.8%+31.8%+25.8%+34.3%+28.0%+23.8%+24.1%+24.4%
Depreciation453447313317299393271257
Interest11012011510891.7689.1066.8970.87
Profit before tax2,0171,9281,5222,0071,4168961,0711,055
Tax600459342522194113212195
Net profit1,4171,4691,1811,4851,221782859859
EPS (₹)30.8934.7525.6732.2826.6216.8718.6918.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue27,95822,70820,01116,64216,40515,16315,375
Revenue growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
Other income1,081202131151210138618
Total expenses20,35617,43016,21114,92116,18712,59613,772
Employee cost4,5753,9643,4953,0872,9892,8262,987
EBITDA7,6025,2783,8001,7212192,5671,603
EBITDA margin+27.2%+23.2%+19.0%+10.3%+1.3%+16.9%+10.4%
Depreciation1,3761,1691,1978811,659887970
Interest434295312274143141363
Profit before tax6,8734,0152,422716(1,372)1,676887
Tax1,5177094872691374491,157
Net profit5,6883,2251,892410(1,561)1,177(470)
Net profit margin+20.3%+14.2%+9.5%+2.5%-9.5%+7.8%-3.1%
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.4491.3291.1491.0090.9090.7490.60
Reserves & surplus22,35717,11214,19912,37412,06213,71212,446
Shareholders' funds (net worth)22,44817,20414,29012,46412,15313,80312,537
Minority interest65.1090.8583.1678.3268.7154.9744.46
Secured loans2,6602,3960.000.00142243176
Unsecured loans3,9563,0522,9224,5424,0174,5406,130
Total debt6,6165,4482,9224,5424,1584,7836,305
Total liabilities29,97323,43418,01617,78917,09919,71120,071
Assets
Gross block23,21720,18419,66518,07715,99014,72714,160
Net block10,9949,7198,8788,3557,3827,8817,938
Capital work in progress1,0165177731,2381,1461,066940
Investments3,6701,1461,0755179002,4552,374
Inventories6,0835,4764,9544,4924,6314,0923,457
Sundry debtors6,6045,4974,6924,4814,2624,4745,446
Cash & bank balances5,6533,1421,2031,2931,0981,7422,454
Loans & advances2,1101,6241,7521,7461,6441,3011,718
Total current assets20,45015,73912,60112,01211,63511,61013,075
Total current liabilities8,1735,5445,7354,9384,4823,6694,713
Net working capital12,27710,1956,8667,0747,1537,9408,362
Total assets29,97323,43418,01617,78917,09919,71120,071
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,5449841,2329919262,229544
Net cash from operating activities7,3343,0003,6481,8973671,8221,469
Net cash from investing activities(3,865)(4,172)(1,712)(1,287)1,292(1,240)1,107
Net cash from financing activities(846)1,732(2,184)(337)(1,572)(1,885)(891)
Net change in cash2,624560(248)27387.22(1,303)1,685
Closing cash5,6533,1421,2031,2931,0981,7422,454
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.1%+13.5%+20.3%+1.4%+8.2%-1.4%-
EBITDA growth+44.0%+38.9%+120.9%+686.3%-91.5%+60.2%-
PBT growth+71.2%+65.8%+238.1%+9998.0%-+88.9%-41.0%
Net income growth+76.4%+70.5%+361.8%+126.2%-232.6%+350.3%-
Revenue CAGR (3Y)+18.9%+11.5%+9.7%+2.7%+3.8%-1.4%-4.0%
EBITDA CAGR (3Y)+64.1%+188.9%+14.0%+2.4%-53.8%+15.1%-29.1%
Profitability & leverage
Net income margin+19.2%+14.6%+9.7%+2.7%-9.2%+8.1%-1.8%
Return on capital employed+27.4%+20.9%+15.3%+5.7%-6.7%+9.2%+8.1%
Return on net worth+27.0%+21.0%+14.5%+3.6%-11.6%+9.3%-3.6%
Debt / equity0.300.270.280.350.340.420.56
Long-term debt / equity0.110.070.010.010.010.070.32
Interest cover6.987.1811.9732.66-9.928.3757.39
Efficiency & per share
Fixed asset turnover1.291.141.060.981.071.051.03
Inventory turnover4.844.354.243.653.764.024.22
Debtors turnover4.624.464.363.813.763.062.90
EPS (₹)116.6471.8742.019.45(33.62)26.81(5.95)
Dividend per share (₹)18.0012.008.004.004.006.506.00
Book value per share (₹)490.99376.77313.59273.95267.40304.23276.75
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1725,2354,5014,0685,7094,4864,2084,106
Revenue growth (YoY)+25.6%+16.7%+7.0%-0.9%+37.0%---
Other income10253799.8066354.1448.7955.3032.62
Total expenses3,4392,9533,5182,8932,9792,7402,8742,991
EBITDA3,7332,2829831,1762,7301,7461,3341,115
EBITDA margin+52.5%+44.3%+22.2%+30.5%+48.7%+39.8%+32.9%+28.4%
Depreciation190177179175177208153146
Interest35.5638.7736.0227.7818.9033.8519.5517.55
Profit before tax3,6102,6028681,6362,5881,5531,217984
Tax895439150278460262232176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19,51316,96814,66611,25911,77211,05611,026
Revenue growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
Other income1,346253116210217129475
Total expenses12,33611,65211,21610,29511,5639,0129,877
Employee cost2,5452,3122,0961,9341,9181,6961,703
EBITDA7,1765,3163,4509642092,0441,148
EBITDA margin+36.8%+31.3%+23.5%+8.6%+1.8%+18.5%+10.4%
Depreciation707648725548514503519
Interest12184.5056.3598.4473.4740.6252.59
Profit before tax7,6944,8372,785527(162)1,6301,052
Tax1,32886445910227.17371325
Net profit5,7744,0002,302411(219)1,2171,153
Net profit margin+29.6%+23.6%+15.7%+3.7%-1.9%+11.0%+10.5%
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital91.4491.3291.1491.0090.9090.7490.60
Reserves & surplus30,04224,18720,51218,32118,05918,47517,383
Shareholders' funds (net worth)30,13424,27820,60318,41218,15018,56617,473
Secured loans0.000.000.000.000.0050.795.29
Unsecured loans1,1152501057499514350.54
Total debt1,1152501057499514855.83
Total liabilities31,87325,03721,13519,55419,43919,40917,937
Assets
Gross block9,0448,6737,6057,4086,7056,2305,666
Net block4,8734,9464,1134,0223,6903,6393,514
Capital work in progress523278446927947951822
Investments15,62511,95511,5819,9749,5119,5637,456
Inventories3,3513,2272,9693,0193,1772,7082,485
Sundry debtors6,9225,6643,8422,6742,7223,1913,616
Cash & bank balances12845913910164.562841,306
Loans & advances1,7691,5411,5291,3361,6521,1141,102
Total current assets12,17010,8918,4797,1317,6157,2968,509
Total current liabilities4,1083,2403,6322,9442,6872,2332,550
Net working capital8,0627,6514,8474,1874,9285,0645,959
Total assets31,87325,03721,13519,55419,43919,40917,937
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash34212485.6659.101771,16855.94
Net cash from operating activities5,5402,4452,5041,7941511,5702,219
Net cash from investing activities(5,649)(1,766)(1,599)(1,269)(372)(2,508)(740)
Net cash from financing activities(121)(460)(867)(498)102(53.17)(368)
Net change in cash(230)21838.0426.56(118)(991)1,112
Closing cash12845913910164.562841,306
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.0%+15.7%+30.3%-4.4%+6.5%+0.3%-
EBITDA growth+35.0%+54.1%+258.0%+360.9%-89.8%+78.0%-
PBT growth+59.1%+73.7%+428.3%+9998.0%-+54.9%-55.1%
Net income growth+44.3%+73.8%+460.5%+287.3%-118.0%+5.5%-
Revenue CAGR (3Y)+20.1%+13.0%+9.9%+0.7%+1.2%+3.1%-4.4%
EBITDA CAGR (3Y)+95.3%+194.0%+19.1%-5.7%-56.3%-0.7%-36.5%
Profitability & leverage
Net income margin+32.6%+23.4%+15.9%+3.8%-1.6%+11.4%+6.6%
Return on capital employed+27.5%+21.3%+14.0%+3.2%-0.6%+9.0%+10.0%
Return on net worth+23.4%+17.7%+11.9%+2.3%-1.2%+7.0%+6.7%
Debt / equity0.030.010.020.050.040.010.00
Long-term debt / equity0.010.010.000.000.010.000.00
Interest cover1.881.812.0723.69-24.082.648.35
Efficiency & per share
Fixed asset turnover2.202.081.951.601.821.862.11
Inventory turnover5.935.484.903.634.004.264.60
Debtors turnover3.103.574.504.173.983.253.00
EPS (₹)139.2587.0151.049.35(4.15)27.7416.06
Dividend per share (₹)18.0012.008.004.004.006.506.00
Book value per share (₹)659.09531.72452.12404.66399.34409.20385.72

To see the full year-wise statements and ratios of Lupin Limited, buy the company report.

Board of directors of Lupin Limited

Lupin has 10 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Vinita Deshbandhu Gupta
Also directs: Lupin Biologics Limited, Lupin Investments Private Limited, Synchem Properties Private Limited and 1 more
Whole-Time Director17 Aug 200125 Years 2 MonthsCurrent
Ramesh Swaminathan
Also directs: Lupin Biologics Limited, Lupin Manufacturing Solutions Limited, Lupin Diagnostics Limited and 4 more
Whole-Time Director26 Mar 20206 Years 6 MonthsCurrent
Nilesh Deshbandhu Gupta
Also directs: Lupin Biologics Limited, Lupin Investments Private Limited, Synchem Properties Private Limited and 5 more
Managing Director01 Sep 201313 Years 1 MonthsCurrent
Manju Deshbandhu Gupta
Also directs: Lupin Manufacturing Solutions Limited, Lupin Diagnostics Limited, Polynova Industries Limited and 1 more
Director01 Apr 201412 Years 6 MonthsCurrent
Kanwar Bir Singh Anand
Also directs: Ufo Moviez India Limited, Tata Chemicals Limited, Bharat Forge Ltd and 2 more
Director12 Aug 20206 Years 2 MonthsCurrent
Mark Daniel Mc DadeDirector28 Jan 20215 Years 8 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Lupin Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sun Pharmaceutical Industries Limited₹54,543 Cr (FY 2025)9.0%Vadodara, Gujarat, India
Dr.Reddy's Laboratories Ltd₹33,741 Cr (FY 2025)17.0%Hyderabad, Telangana, India
Aurobindo Pharma Ltd₹32,346 Cr (FY 2025)9.0%Hyderabad, Telangana, India
Cipla Limited₹28,409 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Lupin Limitedthis company₹27,958 Cr (FY 2026)₹5,687.73 Cr20.3%23.1%19,688Mumbai, Maharashtra, India
Zydus Lifesciences Limited₹23,511 Cr (FY 2025)19.0%Ahmedabad, Gujarat, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Biocon Limited₹16,470 Cr (FY 2025)5.0%Bengaluru, Karnataka, India
Alkem Laboratories Limited₹13,458 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
Glenmark Pharmaceuticals Limited₹13,435 Cr (FY 2025)6.0%Mumbai, Maharashtra, India

To see the full peer comparison of Lupin Limited, buy the company report.

Auditor

Lupin Limited is audited by B S R & Co. LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2024101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 46.80%, foreign institutional investors hold 22.40%, domestic institutional investors hold 24.70% and retail and other public shareholders hold 6.10%.

Promoters: 46.80%DII (Domestic Institutional): 24.70%FII (Foreign Institutional): 22.40%Retail & Others: 6.10%
Sep 2026
QUARTER
46.80% Promoters
24.70% DII (Domestic Institutional)
22.40% FII (Foreign Institutional)
6.10% Retail & Others
Promoter holding - history
Now 46.80% · Sep 2026High 46.90% · Dec 2025Low 46.80% · Sep 2026
45%45.8%46.5%47.3%48%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 46.90%Mar 2026: 46.90%Jun 2026: 46.90%Sep 2026: 46.80%46.90%46.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters46.80%46.90%46.90%46.90%
Public53.20%53.10%53.10%53.10%

Charges & borrowings

Open charges
₹350 Cr
Satisfied charges
₹3,238.99 Cr
Breakdown by lending institutions
Others₹300.00 Cr
State Bank of India₹50.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
18 Feb 2022100545697Others₹100 CrOpen
17 Feb 2022100545484Others₹200 CrOpen
27 Dec 2021100523538State Bank of India₹50 CrOpen
04 Jun 200710056046State Bank of India₹52.1 CrSatisfied
01 Aug 200610014370State Bank of India₹52.1 CrSatisfied

To see the full charge records of Lupin Limited, buy the company report.

Total charge records: 148 View all charges

Deals & funding

Lupin Limited has 46 deals on record (46 market trades); the latest was in October 2025.

Total deals
46
Market trades
46

Deals on record (5 of 46)

WhenDealAmountParties
Oct 2025Market trade₹11.63 CrBuyer: Goldman Sachs Bank Europe Se - Odi
Seller: Goldman Sachs (Singapore) Pte - Odi
Oct 2025Market trade₹16.19 CrBuyer: Goldman Sachs Bank Europe Se - Odi
Seller: Goldman Sachs (Singapore) Pte - Odi
Jul 2025Market trade₹10.02 CrBuyer: State Street Msci Acwi Ex Usa Imi Screened Non-Lending Common Trust Fund
Seller: State Street Msci Acwi Ex Usa Imi Screened Non-Lending Common Trust Fund
Jan 2024Market trade₹108.39 CrBuyer: an individual
Seller: an individual
Jul 2016Market trade₹66.96 CrBuyer: Visiomed Investments Private Limited, Rahas Investments Private Limited
Seller: an individual

To see the full deal history of Lupin Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Lupin Limited has 68 MSME Form 1 returns on record between 2004 and 2024, listing 1,473 overdue payments to 395 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 395)

SupplierAmount dueDue sinceReported on
Kurundam Management Services Private Limited
Shreeshail Chemicals Private Limited
Safetechno Services
an individual supplier
an individual supplier

To see the full MSME payment records of Lupin Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Lupin has 5 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

5
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Lupin Manufacturing Solutions Ltd., India (W.E.F. July 24, 2023)U21001MH2023PLC407210
Lupin Diagnostics Ltd., IndiaU24100MH2011PLC214885
Lupin Biologics Ltd., IndiaU24299MH2021PLC354211
Lupin Digital Health Ltd., IndiaU74999MH2021PLC360783
Lupin Life Sciences Ltd., India (Formerly Known As Lupin Atharv Ability Ltd.)(W.E.F. July 17, 2023)U86100MH2023PLC406793

To see the full group structure of Lupin Limited, buy the company report.

Employees & EPFO

Lupin Limited has a workforce of 19,688 employees on its EPFO records as of Mar 22, 2025, across 12 active EPFO establishments.

Employee count
19,688
Active EPFO establishments
12
Employee growth
0.51%

GST

Lupin has 42 GST registrations: 33 active and 9 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
42
Active
33
Cancelled / inactive
9
GSTINStateStatusRegistered on
27AAACL1069K1ZFMaharashtraActive01 Jul 2017
27AAACL1069K2ZEMaharashtraActive06 Jul 2017
27AAACL1069K3ZDMaharashtraActive23 Jul 2017
03AAACL1069K1ZPPunjabActive01 Jul 2017

To see the full GST registrations and return filing status of Lupin Limited, buy the company report.

Recent activity

Lupin Limited has 47 board changes on record since 1983: 29 appointments and 18 cessations. The latest: Anand Kripalu was appointed as Director on 01 Feb 2026.

Filing
Lupin Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Appointed
Anand Kripalu was appointed as Director.
AGM
Lupin Limited last Annual general meeting of members was held on 11 Aug 2025 as per latest MCA records.
Ceased
Jean Luc Marie Martial Belingard ceased to be Director.
Ceased
Punita Kumar Sinha ceased to be Director.
Appointed
Punita Lal was appointed as Director.
Appointed
Amit Kumar Gupta was appointed as Company Secretary.
Appointed
Alfonso Martin Gimenez Zulueta was appointed as Director.
Appointed
Jeffrey Bruce Kindler was appointed as Director.
Charges
A charge registered on 23 Sep 2002 via Charge ID 90226754 with Central Bank Of India was fully satisfied on 11 Jan 2024.
Ceased
Christine Ann Mundkur ceased to be Director.
Ceased
Kamal Kishore Sharma ceased to be Director.

398 earlier events are in the company report.

News

Lupin: Co Names Brian Savage As New President And Chief Legal Officer, Formerly Worked As EVP And Interim Global CLO At Teva Pharmaceuticals.
23 Oct 2026 · Exchange Update
Lupin: Company Gets US FDA Nod for Phytonadione Injectable Emulsion 1 MG/0.5 ML Pre-filled Syringe.
08 Oct 2026 · Exchange Update
Lupin: Launches Formoflo-g MDI, World’s First Fixed-dose Triple Combination Drug For COPD Management
06 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Lupin is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 March 1983 (43+ years old) and is registered under CIN L24100MH1983PLC029442. Listed on BSE: 500257 and NSE: LUPIN.

Lupin reported revenue of ₹27,958 Cr for FY 2025-26 (up 23.1% YoY) based on consolidated financials.

Lupin has 10 current directors:

The latest financial statements of Lupin on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 11 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Lupin is 27AAACL1069K1ZF, registered in Maharashtra. The company has 42 GST registrations in all, of which 33 are active and 9 are cancelled or inactive. Other active GSTINs include 27AAACL1069K2ZE (Maharashtra), 27AAACL1069K3ZD (Maharashtra), 03AAACL1069K1ZP (Punjab).

The CIN (Corporate Identification Number) of Lupin is L24100MH1983PLC029442. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Lupin is a listed company as per MCA records. Its shares are listed on both BSE (code: 500257) and NSE (symbol: LUPIN).

Lupin has 720 court cases on record: 400 filed by the company and 322 filed against it. 169 are pending. Most are in the high courts.

Lupin was incorporated on 01 March 1983, making it 43+ years old. It is registered with the Registrar of Companies, Mumbai.

Lupin has 46 deals on record (46 market trades); the latest was in October 2025.

The peers of Lupin by revenue are Sun Pharmaceutical Industries Limited, Dr.Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Cipla Limited, Zydus Lifesciences Limited and 5 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Anand Kripalu was appointed as Director on 01 Feb 2026. Jean Luc Marie Martial Belingard ceased to be Director on 11 Aug 2025. Punita Kumar Sinha ceased to be Director on 11 Aug 2025. Lupin has 47 board changes on record in total.